New warnings cover every GLP-1 RA, including semaglutide, tirzepatide, and orforglipron.
News|Videos|November 9, 2026
Medical Aid in Dying: Law, Ethics, and Choice
Advertisement
As laws on medical aid in dying continue to evolve across the US, pharmacists and other health care professionals face complex legal, ethical, and clinical questions. Pharmacy Times® and The American Journal of Managed Care® are partnering to present a multidisciplinary panel spanning medical ethics, psychiatry, law, and patient advocacy. Register for the free webinar to explore eligibility and safeguards, conscientious objection, disability-rights concerns, and the role of palliative and hospice care.
Advertisement
Related to this article
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
If gene therapies are expected to deliver decades of benefit, long-term evidence collection must be coordinated, useful to patients, and financially sustainable.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
3
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
4
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
5